Ma Songjiang 4
4 · GYRE THERAPEUTICS, INC. · Filed Mar 19, 2025
Insider Transaction Report
Form 4
Ma Songjiang
DirectorPresident
Transactions
- Sale
Common Stock
2025-03-17$12.09/sh−2,000$24,180→ 2,829,260 total(indirect: By Spouse) - Sale
Common Stock
2025-03-18$10.24/sh−242$2,478→ 2,829,018 total(indirect: By Spouse)
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.795 to $12.38. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.02 to $10.33. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.